Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Granuloma Annulare Clinical Trial

Official title:

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03910543
• Other study ID #: 2000023910
• Status: Completed
• Phase: Phase 1
• Start date: April 11, 2019
• Est. completion date: June 1, 2021

Study information

• Verified date: July 2021
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.

Description:

An open-label clinical trial of tofacitinib in cutaneous sarcoidosis and GA. The hypothesis is that Janus Kinase (JAK) 1/3 inhibition with tofacitinib will be effective for the treatment these two diseases. Tofacitinib will be administered at a dose of 5 mg twice daily and response to therapy will be assessed at months 1, 3, and 6 of therapy. The primary outcomes will be improvement in the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) and Granuloma Activity Scoring Index (GASI) after 6 months of tofacitinib therapy. Secondary outcomes will include improvement in internal organ sarcoidosis (i.e. lung, cardiac) and skin related quality of life. Pre- and on treatment PET-CT scans will be performed in patients with sarcoidosis with internal organ involvement. Pre- and on treatment blood collection and skin biopsies will be performed for correlative scientific studies using RNA sequencing, immunohistochemistry (IHC), and cytokine profiling.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: June 1, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years old or older
• Diagnosis of cutaneous sarcoidosis or granuloma annulare with supportive skin biopsies in which other causes of granulomas (infectious, foreign body) have been ruled out
• Patients with either: Cutaneous Sarcoidosis Activity and Morphology (CSAMI) activity score greater than or equal to 10 (patients with a CSAMI greater than or equal to 10 have active cutaneous sarcoidosis involving several distinct cutaneous sites and would otherwise be considered candidates for systemic therapy), or any CSAMI score and sarcoidosis involvement causing functional impairment (i.e. nasal or visual field obstruction).
• For patients with granuloma annulare, patients with 5% or greater Body Surface Area (BSA) will be enrolled.
• If patients are on other systemic therapies for their sarcoidosis or granuloma annulare, they must be taking a stable dose of the other medication(s) for at least 3 months with no plans to change the regimen in the next 6 months. With the exception of methotrexate and/or low dose prednisone, use of concomitant immunosuppressants, e.g. infliximab, azathioprine, etc., will not be permitted.
• Females of childbearing potential must agree to use birth control during the study and there must be a negative pregnancy test documented prior to starting the medication.
• Patients must be willing to undergo skin biopsies, blood collection, and total body photography and comply with clinic visits

Exclusion Criteria:

• Age <18 years old
• Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
• Patients known to be HIV or hepatitis B (HBV) or C (HCV) positive (prior exposure to but clearance of HBV and HCV is acceptable for study entry as long as patient is being monitored by hepatology)
• Patients with active tuberculosis or untreated latent tuberculosis as determined by positive tuberculin skin test or positive QuantiFERON® Tuberculosis (TB) test and, as necessary, chest X-ray
• Patients with significant hepatic impairment
• Patients with untreated peptic ulcer disease
• Patients taking immunosuppressive medications, with the exception of methotrexate and/or low- dose prednisone, including but not limited to mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or Tumor Necrosis Factor (TNF-a) inhibitors
• Women of childbearing potential who are unable or unwilling to use birth control while taking the medication
• Women who are pregnant or nursing. If a woman becomes pregnant during the study, she will stop study medication and be removed from the study. She will be urged to follow up with her Primary Care Physician or OB/GYN. The study doctors will ask to follow the pregnancy to its outcome.

Related Conditions & MeSH terms

• Cutaneous Sarcoidosis
• Granuloma
• Granuloma Annulare
• Sarcoidosis

Intervention

Drug:
• Tofacitinib 5 mg twice daily
Tofacitinib will be administered at a dose of 5 mg twice daily

Locations

Country	Name	City	State
United States	Yale Center for Clinical Investigation	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	Pfizer

Country where clinical trial is conducted

United States, 

References & Publications (1)

Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N Engl J Med. 2018 Dec 27;379(26):2540-2546. doi: 10.1056/NEJMoa1805958. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI)	For patients with sarcoidosis: change in CSAMI score after 6 months of treatment with tofacitinib compared to baseline.; The activity portion of the CSAMI score will be utilized. The range of scores is from 0 to 165. Higher scores correspond with higher cutaneous disease burden.; The percentage change in CSAMI score will be calculated as follows: change in CSAMI score = [baseline CSAMI - final CSAMI] / baseline CSAMI; Higher percentage change corresponds to more improvement on therapy (0% = no change, 100% = complete disease resolution) Negative percentage change corresponds to disease worsening (-25% = 25% worsening of disease)	6 - 12 months
Primary	Percent Change in Body Surface Area (BSA) involvement by GA lesions	For patients with GA: change in BSA involvement after 6 months of treatment with tofacitinib compared to baseline.; The range of BSA involvement for this study is from 5% to 100%. Higher BSA involvement corresponds with higher cutaneous disease burden.; The percentage change in BSA will be calculated as follows: Change in BSA = [baseline BSA- final BSA] / baseline BSA Higher percentage change corresponds to more improvement on therapy (0% = no change, 100% = complete disease resolution) Negative percentage change corresponds to disease worsening (-25% = 25% worsening of disease).	6 - 12 months
Secondary	Change in Skindex-16: a skin-related quality of life metric	For all patients: change in Skindex-16 score after 6 months of treatment with tofacitinib compared to baseline	6 - 12 months
Secondary	Change in Histologic Findings	Skin biopsies of lesional skin will be performed at baseline and again after 6 months of treatment. Standard hematoxylin and eosin (H&E) and immunohistochemistry for CD68, phospho-STAT1, and phospho-STAT3 will be performed.	6 -12 months
Secondary	Change in RNA sequencing markers (gene expression analysis)	RNA sequencing will be performed on RNA extracted from skin biopsies of lesional skin at baseline and again after 6 months of treatment.	6 - 12 months
Secondary	Change in cytokine biomarkers	Luminex-based cytokine analysis using a commercially available service will be performed on plasma collected at baseline and again after 6 months of treatment.	6 - 12 months
Secondary	Change in activity of internal organ sarcoidosis	For patients with sarcoidosis: change in PET-CT imaging after 6 months of treatment with tofacitinib compared to baseline	6 - 12 months